Overview / Abstract: |
Advances in molecular genetics and testing have refined the diagnosis, treatment, and follow-up for patients with BRCA and other familial genetic syndromes. As women with germline BRCA1 and BRCA2 mutations are at an increased risk for developing high-grade serous ovarian cancer, there are implications for genetic testing, family counseling, radiologic screening, and pharmaceutical choices in the community setting. Molecular and genetic advances, such as novel PARP inhibitors, are altering the treatment paradigm for recurrent ovarian cancer. Other familial cancer genetic syndromes are being rapidly identified and may have implications for screening, diagnosis, and treatment of those malignancies. |
Expiration |
Feb 20, 2019 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
AACME - 1.00 AMA PRA Category 1 Credit; ACPE - 1.00 hours (0.1 CEUs); ANCC - 1.0 contact hours; |
Accreditation |
AACME, ACPE, ANCC |
Presenters / Authors / Faculty |
Jennifer Billiet, MGC, CGC |
Activity Specialities / Related Topics |
Genetics, Hematology, Oncology / Cancer / Radiation Therapy, Pharmacology |
Sponsors / Supporters / Grant Providers |
This activity is supported by independent educational grants from AstraZeneca, Genentech, Lilly, and Novartis Pharmaceuticals Corporation. For further information concerning Lilly grant funding visit www.lillygrantoffice.com. |
Keywords / Search Terms |
Rockpointe genetics, familial associated cancers, BRCA1, BRCA2, Free CME, CME, Registered Nurse, Nurse Practitioner, Physician, Pharmacology, oncology Free CE CME |